ISPOR Reporting Guidelines for Comparative Effectiveness Research (original) (raw)

Guide to Statistics and Methods

Reporting Guidelines

April 7, 2021

JAMA Surg. 2021;156(7):673-674. doi:10.1001/jamasurg.2021.0534

visual abstract icon editorial comment icon author interview icon Interviews multimedia icon Multimedia audio icon

Full Text

Randomized clinical trials (RCTs) are considered the main source of data driving evidence-based practice and the primary method for establishing the efficacy of an intervention. However, for a variety of reasons, the universe of research questions that can be definitively addressed by traditional RCTs is limited.1 At the heart of comparative effectiveness research (CER) is a desire to generate real-world evidence demonstrating the effectiveness (rather than the efficacy) of an intervention using real-world data (obtained outside the often-ideal conditions of a traditional RCT). As value-based reimbursement models are better integrated into the US health care system and patient-centered care is increasingly emphasized, there will be a greater need for high-quality CER studies to inform the most clinically effective and cost-effective treatments and to help identify the right type of treatment for patients being treated in specific clinical contexts.

Full Text